Benolizime

This classification denotes a sedative and hypnotic with the molecular formula C19H26N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7RE4N644YF, chemically known as 1,2,3,4,4a,6,7,11b,12,13a-decahydro-9, 10-dimethoxy-13h-dibenzo(a,f)quinolizin-13-one oxime but more generally known as benolizime, which bears US NIH Compound Identifier 9578100. European Medicines Agency schedules Benolizime in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05721MIG. The term BENOLIZIME is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 35, No. 5 1981, List 21). BENOLIZIME is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule benolizime under HS 29339990 and SITC 51577. As of Q4 2014, BENOLIZIME remains the US FDA Preferred Term for this commodity. Benolizime bears US NLM identifiers UMLS ID C2698362 and NCI Concept Code C77242. SMILES: O/N=C1/C2C(N3C(C1)C1C(CC3)CC(OC)C(OC)C1)CCCC2.